Last reviewed · How we verify
Scilin®M30
Scilin®M30 is a premixed insulin formulation that combines rapid-acting and intermediate-acting insulin to control blood glucose in diabetes.
Scilin®M30 is a premixed insulin formulation that combines rapid-acting and intermediate-acting insulin to control blood glucose in diabetes. Used for Type 2 diabetes mellitus, Type 1 diabetes mellitus.
At a glance
| Generic name | Scilin®M30 |
|---|---|
| Sponsor | Chinese Diabetes Society |
| Drug class | Premixed insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a fixed-ratio insulin mixture containing 30% rapid-acting insulin and 70% intermediate-acting insulin (NPH). It provides both immediate postprandial glucose control and basal insulin coverage, mimicking physiological insulin secretion patterns. The combination allows for simplified dosing regimens in patients requiring insulin therapy.
Approved indications
- Type 2 diabetes mellitus
- Type 1 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Scilin®M30 CI brief — competitive landscape report
- Scilin®M30 updates RSS · CI watch RSS
- Chinese Diabetes Society portfolio CI